Literature DB >> 21355803

Long-term evaluation of the use of Ahmed gonioimplants in dogs with primary glaucoma: nine cases (2000-2008).

Hans D Westermeyer1, Diane V H Hendrix, Daniel A Ward.   

Abstract

OBJECTIVE: To evaluate the outcome and describe the complications associated with use of an Ahmed gonioimplant in the treatment of glaucoma in dogs.
DESIGN: Retrospective case series. ANIMALS: 9 client-owned sighted dogs (median age, 9 years) with primary glaucoma. Procedures-Medical records of dogs with primary glaucoma that underwent unilateral gonioimplant placement (in 2000 through 2008), during which a temporalis muscle fascia graft (n = 8) or porcine intestinal submucosa (1) was used to cover the implant tube as it exited the globe, were reviewed. All dogs were treated with mitomycin C in the conjunctival pocket intraoperatively and with tissue plasminogen activator immediately after surgery; 1% prednisolone acetate was applied to the implanted eye daily until failure of the implant. Medical intervention or additional surgery was performed when intraocular pressures (IOPs) were > 20 mm Hg or progressively increasing values were detected.
RESULTS: After gonioimplant placement, IOP was controlled for a variable period in all dogs. Subsequently, IOP exceeded 20 mm Hg in 7 dogs (median postoperative interval, 326 days). Median interval to vision loss despite interventional surgery was 518 days (range, 152 to 1,220 days). Surgical intervention was necessary in 4 dogs to maintain satisfactory IOP. Implant extrusion attributable to conjunctival dehiscence or necrosis occurred in 4 dogs. At 365 days after surgery, 8 dogs retained vision, and 5 dogs retained vision throughout follow-up. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs with medically refractory primary glaucoma, placement of a gonioimplant appears to be effective in maintaining vision.

Entities:  

Mesh:

Year:  2011        PMID: 21355803     DOI: 10.2460/javma.238.5.610

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  3 in total

1.  Animal models of scarring control.

Authors:  David L Williams
Journal:  Eye (Lond)       Date:  2019-12-10       Impact factor: 3.775

Review 2.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

Review 3.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.